Transaction DateRecipientSharesTypePriceValue
17th November 2020Advisors Llc Orbimed868,016Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$8,680.16
17th November 2020Advisors Llc Orbimed765,992Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$7,659.92
17th November 2020Advisors Llc Orbimed434,008Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$4,340.08
17th November 2020Advisors Llc Orbimed434,008Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$4,340.08
17th November 2020Advisors Llc Orbimed1,531,984Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$15,319.84
17th November 2020Advisors Llc Orbimed765,992Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.01$7,659.92
2nd October 2020Advisors Llc Orbimed200,000Open or private purchase$25.00$5,000,000.00
2nd October 2020Advisors Llc Orbimed296,000Open or private purchase$25.00$7,400,000.00
1st October 2020Advisors Llc Orbimed296,296Open or private purchase$6.00$1,777,776.00
1st October 2020Advisors Llc Orbimed46,784,775Grant/award etc.$1.07$50,059,709.25
Prevail Therapeutics
Prevail Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.


Ticker: PRVL
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1714798
Employees: 55
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals